/ Kills / LONGEVITY KILL
LONGEVITY KILL
“Outlive your enemies.”
// 01
Summary.
The quarterly maintenance protocol. Pineal rhythm, thymic signalling, and cellular NAD+ availability. This is the one people run forever, in pulses, rather than in a single hard cycle.
It is also the protocol where the foundation matters most: without sleep, sunlight and protein, this stack is an expensive placebo. Run S.T.A.R.T.E.D. first.
// 02
The stack.
Peptide · 01
EPITALON
Pineal tetrapeptide
Circadian entrainment and telomerase-adjacent signalling.
20 mg / vial
Peptide · 02
THYMALIN
Thymic peptide complex
Immune signalling support in older adults.
10 mg / vial
Peptide · 03
NAD+
Nicotinamide adenine dinucleotide
Cellular energy metabolism and DNA-repair cofactor.
500 mg / vial
// 03
Reconstitution.
EPITALON · 20 mg vial + 2 mL bac water
1 mg (10 units) SubQ nightly · 10–20 day pulse
THYMALIN · 10 mg vial + 2 mL bac water
1 mg (10 units) SubQ · 10-day pulse
NAD+ · route and dose vary widely (SubQ, IV, oral precursor).
Start very low. SubQ NAD+ stings and flushes.
Cycle: 10–20 day pulse, quarterly. Not continuous.
// 04
Dosing table.
| Level | Stack | Units (U-100) | Freq |
|---|---|---|---|
| PULSE | EPITALON | 10 | Nightly · 10–20 d |
| PULSE | THYMALIN | 10 | Daily · 10 d |
| VARIES | NAD+ | start low | Per tolerance |
Per-compound vial math: CJC + IPA · IPAMORELIN
// 05
Cycle & timing.
PULSE
10–20 DAYS
Quarterly. Four pulses a year is the common pattern in the registry.
OFF
REST OF QUARTER
Foundation only. STARTED does the work between pulses.
// 06
Contraindications.
- —Active malignancy (EPITALON has growth-regulatory activity).
- —Pregnancy / lactation. No data.
- —Autoimmune disease under active treatment — discuss THYMALIN with your physician first.
- —NAD+ infusions: cardiac history warrants a clinician.
// 07
Evidence.
RUSSIAN LITERATURE
EPITALON and THYMALIN carry a decades-long Eastern European clinical literature that has never been replicated at Western regulatory standard. Read it as signal, not proof.
NAD+
NAD+ biology is well characterized. Whether exogenous NAD+ raises intracellular levels meaningfully is still contested.
REGISTRY
Long-horizon protocols are the hardest to evaluate and the most worth logging. Quarterly entries matter.
// 09
Adverse events.
MILD
0
MODERATE
0
SEVERE
0
// 10
Related kills.
RECOVERY KILL
“Heal like you borrowed the body.”
SLEEP KILL
“Die better at night.”
FAT KILL
“Not a diet. A vendetta.”
// Disclaimer
Nothing on killer.health is medical advice. This platform is a research registry and information aggregator. Content is drawn from peer-reviewed publications, clinical protocols and community sources. killer.health does not endorse any compound, supplier or treatment. Always work with a licensed physician inside an established clinical relationship before starting, stopping or modifying any protocol. Data capture is governed by IRB PPRN-001-2025. Anonymous submissions are the default.